MARB: Molecular Analysis of Retinoblastoma

Categories:

Tissue Bank

Supportive Solid Tumor Studies

Eligibility Overview:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

Description

Retinoblastoma is a childhood tumor that affects the retina portion of the eye. These tumors form because of a gene inactivation that occurs before birth. This gene is known as RB1. Children who inherit one abnormal copy of RB1 are likely to develop retinoblastoma affecting both eyes. Children who randomly inherit the gene usually have retinoblastoma involving only one eye. Treatment for retinoblastoma includes removing the diseased eye during an operation in the more advanced cases.

Researchers want to look at a sample of the tumor tissues removed during the operation. They want to learn more about what makes these tumor cells grow and why. They would also like to collect a sample of the participants’ blood, and some information about the child’s age, family history and the stage of the tumor to compare with other tissues and blood samples obtained in the study.

Objective

  • To study retinoblastoma cells in the laboratory
  • To see if any of these studies are associated with the chance of the tumor spreading
  • To compare findings in blood and cancer cells

Eligibility

  • Participant is undergoing surgery for suspected retinoblastoma
  • Participant is able to provide 1 teaspoon of blood

Principal Investigator

Rachel Brennan, MD

St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105  USA
Voice: 1-888-226-4343 or 901-595-4055
24-Hour Emergency Access Pager: 1-800-349-4334
Email: referralinfo@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.